Clinical Performance of the Gedea Pessary in Adult Women With Vulvovaginal Candidiasis

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

26 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-03-16

Study Completion Date

2024-03-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a multi-centre, multi-national study to evaluate the clinical performance and safety of treatment with Gedea Pessary in adult women with confirmed vulvovaginal candidiasis (VVC).

The study population will consist of post-menarchal, pre-menopausal females, 18 years or older, seeking care for VVC symptoms. A total of 26 patients are planned to be included in the study. On Day 0 (Screening, Visit 1), eligible patients will undergo a gynaecological examination, including collection of composite vulvovaginal signs-and-symptoms (CVVS) score data, and vaginal samples. Patients will be provided with 6 doses of Gedea Pessary that will be self-administered as a daily treatment (Days 0 to 5).

Patients will visit the clinic on Day 7 (+2 days, Visit 2) for gynaecological examinations, including collection of CVVS data for the assessment of clinical cure and reporting of AEs and concomitant medications. On Day 14 (±2 days, Visit 3), patients that did not have a clinical and mycological cure Day 7 will re-visit the clinic for additional gynaecological examinations, including collection of CVVS data for the assessment of clinical cure. Rescue treatment will be offered during visits 2 and 3, if necessary. Patients will have a final telephone follow-up on Day 25 (±3 days, Visit 4), for for reporting of AEs, concomitant medications and potential menstruation onset. Vaginal sampling for culture and sequencing, as well as vaginal pH measurements will be performed at the clinic on Day 0, Day 7, and Day 14. On Day 25, patients will self-perform vaginal swabs at home for sequencing and vaginal culture. Patient questionnaires for assessing VVC symptoms, will be used during the treatment period (Days 0 to 5), 1 day after the treatment (Day 6) and on Days 11 and 25. Usability will be assessed on Day 7, also via the patient questionnaire. The patient questionnaire will be based on an electronic patient reported outcomes (ePRO) system, i.e. a mobile application (ViedocMe™).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Performance of a Vaginal Pessary (pHyph) in Vulvovaginal Candidiasis

NCT03761628

Vulvovaginal Candidiasis

COMPLETED NA

Clinical Performance of a Vaginal Pessary (pHyph) in Bacterial Vaginosis

NCT03762083

Bacterial Vaginosis

COMPLETED NA

Clinical Performance and Safety of the Gedea Pessary in Adult Women With Bacterial Vaginosis

NCT04640922

Bacterial Vaginosis

COMPLETED NA

A Randomised, Partly-blinded Investigation to Evaluate the Clinical Performance and Safety of pHyph in Adult Women With Bacterial Vaginosis Compared With an Untreated Control Group

NCT06123299

Bacterial Vaginosis

COMPLETED NA

Evaluation of VagiVitalAC for Treatment of Candida Vulvovaginitis

NCT05012852

Vaginal Candidiasis Vulvovaginal Candidiasis Candidal Vulvovaginitis

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vulvovaginal Candidiasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Gedea pessary

Gedea pessary administration

Group Type OTHER

pHyph generation II

Intervention Type DEVICE

Daily administration of the Gedea pessary during 6 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

pHyph generation II

Daily administration of the Gedea pessary during 6 days

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Gedea pessary

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Having decisional capacity and providing written informed consent.
2. Adult, post-menarchal, pre-menopausal women, aged 18 years or older
3. Diagnosis of VVC, defined as:

* Having a white or creamy vaginal discharge
* At least 2 of the following signs and symptoms of VVC that are characterised as at least moderate: itching, burning, irritation, oedema, erythema, or excoriation.
* KOH or saline preparation from the inflamed vaginal mucosa or secretions revealing yeast forms (hyphae or pseudohyphae) or budding yeasts.
4. Negative urine pregnancy test at Screening.
5. Refrain from using any intravaginal products (i.e. contraceptive creams, gels, foams, sponges, lubricants, or tampons, etc.) until Day 14.
6. Refrain from sexual intercourse or use a condom until Day 7.
7. Signed informed consent and willing and able to comply with all study requirements.

Exclusion Criteria

1. Patients with known or apparent signs of other infectious causes of vaginal infection (BV, Trichomonas vaginalis, Neisseria gonorrhoeae, Chlamydia trachomatis, Herpes simplex, or human papillomavirus) at Screening.
2. Patients who are pregnant or breastfeeding.
3. Patients who were treated for VVC within 14 days prior to Screening.
4. Patients who are currently receiving anti-fungal therapy unrelated to VVC or has taken anti-fungal therapy within 14 days prior to Screening.
5. Patients who have received an investigational drug in a clinical investigation within 30 days prior to Screening.
6. Known/previous allergy or hypersensitivity to any product constituent or fluconazole.
7. Any medical condition that in the Investigator's judgements would make the patient unsuitable for inclusion.
8. More than 3 previous VVC infections during the last 12 months.

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No